Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
BMGL · Nasdaq · United States · Services-Offices & Clinics Of Doctors Of Medicine
In shortBasel Medical Group Ltd is loss-making, burns cash and carries moderate debt, with revenue growing (+12.6% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | – | n/a |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -94.0% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -163.6% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | – | n/a |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.31× | 42/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.48× | 29/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | – | n/a |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | -40.6% | 0/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 1 of 2 | 37/100 |
Weight in the score: 20%
| Profitable years (last 5) | 1 of 2 | 50/100 |
|---|---|---|
| Years of revenue decline (last 5) | 0 of 1 | 100/100 |
| Revenue growth volatility | – | n/a |
| Operating margin volatility | – | n/a |
Weight in the score: 20%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
The last 2 fiscal years from the company's annual reports.
SGD millions; negative values in parentheses.
| Fiscal year | FY24 | FY25 |
|---|---|---|
| Revenue | 10 | 11 |
| Interest expense | 0.2 | 0.2 |
| Pre-tax income | 2.4 | (11) |
| Income tax | 0.3 | (0.4) |
| Net income | 2.1 | (11) |
| Diluted EPS | SGD0.13 | −SGD0.57 |
| Diluted shares (millions) | 16 | 19 |
Not computed: a required balance-sheet item is missing.
1/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2025 · Data updated Mar 13, 2026